- The FDA has finally responded to the Citizen's Petition filed against Cassava Sciences by the law firm Labaton Sucharow - on behalf of short sellers.
- The agency won't be taking any action - at least in response to the petition - although it didn't rule out conducting its own investigation.
- Cassava stock hasn't moved on the news but the short float was at 35% in mid-January and the battle between bulls and bears continues to rage.
- I take a deeper dive look at the FDA's response and recap on Cassava's journey to date with its Alzheimer's drug Simufilam.
- Listed Alzheimer's drug developers have taken investors on a white-knuckle ride over the past 12 months - Cassava's reading out Phase 3 data this year will be seismic one way or the other.
For further details see:
Cassava Sciences: Interpreting FDA's Response To Citizen's Petition